FibroGen’s Strategic Moves and Clinical Prospects Drive Buy Rating

H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on FibroGen today and set a price target of $43.00.

Matthew Keller has given his Buy rating due to a combination of factors surrounding FibroGen’s recent strategic moves and clinical prospects. The completion of the sale of FibroGen China to AstraZeneca for approximately $220 million has notably strengthened the company’s financial position. This transaction not only exceeded initial expectations by $60 million but also allowed FibroGen to simplify its balance sheet by repaying a significant term loan. The resulting extension of the company’s cash runway into 2028 provides a solid foundation for advancing their clinical programs without financial interruptions.
Furthermore, the positive developments in FibroGen’s clinical pipeline, particularly regarding the upcoming Phase 3 trial for roxadustat, contribute to the Buy rating. The trial, which targets anemia in patients with LR-MDS and high transfusion burden, has been designed following a favorable meeting with the FDA. The agreement on trial details, including patient population and dosing regimen, underscores the potential for successful outcomes. Keller’s valuation model, which factors in the clinical net present value of FibroGen’s assets, supports the optimistic outlook, with key areas of potential upside including new partnerships and the advancement of preclinical assets into clinical development.